PUBLISHER: The Insight Partners | PRODUCT CODE: 1562242
PUBLISHER: The Insight Partners | PRODUCT CODE: 1562242
The North America myopia treatment market was valued at US$ 3,938.90 million in 2022 and is expected to reach US$ 7,335.26 million by 2030; it is estimated to register a CAGR of 8.1% from 2022 to 2030.
Rising Prevalence of Myopia Fuels North America Myopia Treatment Market
The rising prevalence of myopia globally represents a significant public health concern, with increasing incidences observed among children and young adults, particularly. A recent study estimated that by 2050, nearly 50% of the world's population-or 5 billion people-will be myopic, up from the current average of 30%. The frequency of myopia is also increasing in the US; it has been reported to be 42%, nearly doubling in just three decades. Multiple factors contribute to this trend, including lifestyle changes, increased urbanization, and extensive near-work activities, such as prolonged use of digital devices and limited outdoor exposure. While genetic predisposition plays a role, environmental factors also contribute to escalating the rates of myopia substantially. The impact of these lifestyle and environmental factors has led to an enhanced understanding of the complex interplay between genetic susceptibility and environmental influences, further underscoring the need for comprehensive strategies to address this burgeoning public health issue. As the prevalence of myopia continues to rise, there is a growing emphasis on developing proactive interventions, public health campaigns, and innovative treatment approaches to mitigate the long-term implications of high myopia and its associated ocular complications, thereby emphasizing the importance of addressing this multifaceted global health challenge.
North America Myopia Treatment Market Overview
The North America myopia treatment market has been segmented into the US, Canada, and Mexico. The US holds the largest share of the North America myopia treatment market. The market growth in the US will be due to factors such as the growing myopia-related occurrences of vision loss and rising incidence of distant vision impairment from untreated myopia. Furthermore, the rising government support for eye health and technological advancements are prominent factors propelling the North America market growth.
The US myopia treatment market is expected to experience significant growth in the coming years. The prevalence of myopia has been increasing in recent years, which is driving the demand for effective treatments. The US has reported a prevalence of 42%, nearly doubling in just three decades, according to data released by the Myopia Institute in 2023. Furthermore, increasing awareness about myopia is also driving market growth. For instance, the Brien Holden Vision Institute's 2024 Myopia Awareness Week has selected Review of Myopia Management as its official co-sponsor. The collaboration will assist in expanding the reach of Myopia Awareness Week, which is scheduled for domestically and internationally, May 13-19, 2024. More people are becoming aware of the risks associated with myopia, such as an increased risk of developing other eye conditions-cataracts and glaucoma. This has led to a greater demand for effective treatments that can help prevent or slow down the progression of myopia. Another factor driving the growth of the myopia treatment market in the US is the availability of advanced technologies and treatments. Various treatments for myopia are now available, including corrective lenses, orthokeratology, and pharmacological treatments. These treatments are becoming increasingly sophisticated and effective, helping drive demand for myopia treatment. Finally, the growing prevalence of myopia among children is also driving the growth of the myopia treatment market in the US. As more children are diagnosed with myopia, there is a greater need for effective treatments that can help prevent or slow down its progression. This has led to increased investment in research and development of new treatments specifically designed for children. Overall, the US myopia treatment market is expected to grow in the coming years as more people become aware of the condition and demand for effective treatments increases.
North America Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)
North America Myopia Treatment Market Segmentation
The North America myopia treatment market is categorized into type, treatment, age group, end user, and country.
Based on type, the North America myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest North America myopia treatment market share in 2022.
In terms of treatment, the North America myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest North America myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
By age group, the North America myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger North America myopia treatment market share in 2022.
Based on end user, the North America myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest North America myopia treatment market share in 2022.
Based on country, the North America myopia treatment market is categorized into the US, Canada, and Mexico. The US dominated the North America myopia treatment market share in 2022.
Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Topcon Healthcare Solutions Inc, Ziemer Ophthalmic Systems AG, Nidek Co Ltd, Eyes Vision SL, Haag-Streit AG, and Carl Zeiss AG. are some of the leading companies operating in the North America myopia treatment market.